Stratec SE
XETRA:SBS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26.45
48.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Stratec SE
Stratec SE
Total Equity
Stratec SE
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Stratec SE
XETRA:SBS
|
Total Equity
€227.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Carl Zeiss Meditec AG
XETRA:AFX
|
Total Equity
€2.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
|
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
|
Total Equity
€248.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Siemens Healthineers AG
XETRA:SHL
|
Total Equity
€18.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Draegerwerk AG & Co KGaA
XETRA:DRW8
|
Total Equity
€1.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
Sartorius AG
XETRA:SRT
|
Total Equity
€2.7B
|
CAGR 3-Years
29%
|
CAGR 5-Years
26%
|
CAGR 10-Years
21%
|
|
Stratec SE
Glance View
STRATEC SE engages in the design and manufacture of automated analyzer systems in the fields of clinical diagnostic and biotechnology. The company is headquartered in Birkenfeld, Baden-Wuerttemberg and currently employs 1,398 full-time employees. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.
See Also
What is Stratec SE's Total Equity?
Total Equity
227.8m
EUR
Based on the financial report for Sep 30, 2024, Stratec SE's Total Equity amounts to 227.8m EUR.
What is Stratec SE's Total Equity growth rate?
Total Equity CAGR 10Y
8%
Over the last year, the Total Equity growth was 1%. The average annual Total Equity growth rates for Stratec SE have been 4% over the past three years , 9% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet
